PMID- 37993346
OWN - NLM
STAT- Publisher
LR  - 20231122
IS  - 2405-4569 (Electronic)
IS  - 2405-4569 (Linking)
DP  - 2023 Nov 21
TI  - Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guerin Instillations 
      for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box?
LID - S2405-4569(23)00249-3 [pii]
LID - 10.1016/j.euf.2023.11.007 [doi]
AB  - Adjuvant bacillus Calmette-Guerin (BCG) instillations represent a cornerstone in 
      the treatment of non-muscle-invasive bladder cancer. Instillation schedule and 
      dose modifications have been evaluated in efforts to reduce the incidence of 
      adverse events (AEs), but none so far has the same treatment efficacy as the 
      full-dose recommended schedule. It has been shown that prophylactic quinolone use 
      in conjunction with BCG instillations reduces AE incidence and improves timely 
      completion of instillation regimens and patient survival. However, the European 
      Medicines Agency imposed restrictions on the use of quinolones in 2019 because of 
      side effects. Nevertheless, rational use of quinolone prophylaxis could be 
      considered for selected individuals treated with BCG without risk factors for 
      quinolone-associated side effects in conjunction with patient information about 
      side-effect symptoms. PATIENT SUMMARY: Bladder instillations of BCG (bacillus 
      Calmette-Guerin) are used in the treatment of non-muscle-invasive bladder cancer. 
      Antibiotics from the quinolone class can reduce the adverse effects of BCG and 
      help patients in completing the treatment course; however, these antibiotics have 
      their own side effects. Our mini review suggests that the antibiotics could be 
      used in selective cases if patients are given adequate information on these side 
      effects and their symptoms.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Liedberg, Fredrik
AU  - Liedberg F
AD  - Department of Urology, Skane University Hospital, Malmo, Sweden; Institute of 
      Translational Medicine, Lund University, Malmo, Sweden. Electronic address: 
      fredrik.liedberg@med.lu.se.
FAU - Xylinas, Evanguelos
AU  - Xylinas E
AD  - Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Universite de Paris 
      Cite, Paris, France.
FAU - Gontero, Paolo
AU  - Gontero P
AD  - Department of Urology, Citta della Salute e della Scienza, University of Torino 
      School of Medicine, Torino, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231121
PL  - Netherlands
TA  - Eur Urol Focus
JT  - European urology focus
JID - 101665661
SB  - IM
EDAT- 2023/11/23 00:41
MHDA- 2023/11/23 00:41
CRDT- 2023/11/22 22:01
PHST- 2023/09/02 00:00 [received]
PHST- 2023/10/31 00:00 [revised]
PHST- 2023/11/10 00:00 [accepted]
PHST- 2023/11/23 00:41 [medline]
PHST- 2023/11/23 00:41 [pubmed]
PHST- 2023/11/22 22:01 [entrez]
AID - S2405-4569(23)00249-3 [pii]
AID - 10.1016/j.euf.2023.11.007 [doi]
PST - aheadofprint
SO  - Eur Urol Focus. 2023 Nov 21:S2405-4569(23)00249-3. doi: 
      10.1016/j.euf.2023.11.007.